The DOI matches its Crossref record; 178 of the 180 references it cites were found in a registry or an index; 28 of the 41 sources its claims cite were checked for support.
The Mitochondrial Genome in Aging and Disease and the Future of Mitochondrial Therapeutics
Open accessAbstract
Mitochondria are intracellular organelles that utilize nutrients to generate energy in the form of ATP by oxidative phosphorylation. Mitochondrial DNA (mtDNA) in humans is a 16,569 base pair double-stranded circular DNA that encodes for 13 vital proteins of the electron transport chain. Our understanding of the mitochondrial genome’s transcription, translation, and maintenance is still emerging, and human pathologies caused by mtDNA dysfunction are widely observed. Additionally, a correlation between declining mitochondrial DNA quality and copy number with organelle dysfunction in aging is well-documented in the literature. Despite tremendous advancements in nuclear gene-editing technologies and their value in translational avenues, our ability to edit mitochondrial DNA is still limited. In this review, we discuss the current therapeutic landscape in addressing the various pathologies that result from mtDNA mutations. We further evaluate existing gene therapy efforts, particularly allotopic expression and its potential to become an indispensable tool for restoring mitochondrial health in disease and aging.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review surveys the therapeutic landscape for mitochondrial DNA (mtDNA) pathologies, arguing that gene-editing approaches remain narrow in scope while allotopic expression (AE)—recoding mtDNA genes for nuclear expression—holds the most promise for reversing mtDNA mutation symptoms. It highlights codon optimization as a key advance enabling stable nuclear expression of several OXPHOS subunits.
Key findings
- Human mtDNA is a 16,569 base pair circular genome encoding 37 genes: 13 proteins, 22 tRNAs, and 2 rRNAs; all 13 proteins are subunits of the five OXPHOS complexes.
- In a study of 1511 women aged 17–85, mtDNA heteroplasmy increased with age and mtDNA copy number decreased by an average of 0.4 copies per year in isolated PBMC mitochondria.
- Codon optimization enabled stable expression of Complex I genes (ND1, ND2, ND3, ND4, ND4L, ND6), COX2 (Complex IV), and ATP8 (Complex V) in mammalian cells; co-expression of codon-optimized ATP8 and recoded ATP6 rescued a severe phenotype in an ATP8-null patient cybrid line.
- A gRNA designed for mitochondrial matrix import via PNPase achieved ~75% reduction in mtDNA in mouse embryonic fibroblasts targeting the 11205G sequence in mt-ND4.
- In LHON trials, rAAV2–ND4 intravitreal gene therapy was safe with visual improvements reported, but patients recovered vision in both treated and untreated eyes, complicating efficacy conclusions.
Methods
- Narrative review; no primary experimental data reported.
- Synthesizes literature on mtDNA biology, mitochondrial disease genetics, small-molecule and cell-replacement therapeutics, gene-editing tools (mitoREs, ZFNs, TALENs, base editors, CRISPR/Cas), and allotopic expression studies.
- Discusses clinical trial evidence (ClinicalTrials.gov identifiers NCT02161380, NCT03293524, NCT02064569, NCT02427178) and animal model data for ND4, ND6, and ATP6 AE.
Limitations
- Stated: AE faces hydrophobicity-driven cytosolic aggregation (e.g., CYB), incomplete MTS cleavage, and inefficient import; codon optimization does not address targeting, import, or hydrophobicity challenges.
- Stated: paucity of animal models—severe mtDNA mutations are often non-viable, cybrid lines have shifting heteroplasmy, and iPSC models show heterogeneity in mutation loads.
- Stated: LHON clinical trials lack meaningful placebo control, making efficacy difficult to conclude with high confidence; AAV insert capacity (<5 kb) prevents delivery of more than one gene.
- Evident from the text: as a review, no new experimental validation is presented; several cited AE results (e.g., ATP6 mouse studies) are described as mixed or failing to show robust expression.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
28 of 41 cited sources checked · 15 supported · 0 flagged · accuracy not yet measured
- Premisecitation
Human artificial chromosomes (HACs) are capable of large insertions that can be maintained episomally under physiological conditions.
“Another alternative is to place such transgenes in human artificial chromosomes (HACs) capable of large insertions that can be maintained episomally under physiological conditions [172].”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [172] Kazuki, 2011, Human artificial chromosomes for gene delivery and the development of animal models, Mol. Ther. source
- Premisecitation
Quality and quantity of mtDNA is closely linked to mitochondrial function.
“Quality and quantity of mtDNA is closely linked to mitochondrial function [9,10]”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [9] Ashar, 2017, Association of mitochondrial DNA copy number with cardiovascular disease, JAMA Cardiol. source
- cites [10] Herbers, 2019, Tissue specific differences in mitochondrial DNA maintenance and expression, Mitochondrion source
The Abstract says mtDNA is essential for mitochondrial oxidative phosphorylation, and the Concluding Remarks link failures of genome integrity to possible disease effects. But the manuscript explicitly says the relevance of mtDNA levels to mitochondrial function is unclear, so it does not support the claim that mtDNA quantity is closely linked to function. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Premisecitation
Recent advances in generating induced pluripotent stem cells (iPSCs) from primary cells of affected patients have led to the creation of model cell lines with specific mtDNA mutations.
“Recent advances in generating induced pluripotent stem cells (iPSCs) from primary cells of affected patients has also led to the creation of model cell lines with specific mtDNA mutations [160,161,162].”
Quote in the paperNot a substantial claim2 of 3 sources checked- cites [160] Singh, P., Bahr, T., Zhao, X., Hu, P., Daadi, M., Huang, T., and Bai, Y. (2021). Creating Cell Model 2.0 Using Patient Samples Carrying a Pathogenic Mitochondrial DNA Mutation: iPSC Approach for LHON. Methods Mol. Biol., 1–13. source
- cites [161] Meshrkey, 2021, Quantitative analysis of mitochondrial morphologies in human induced pluripotent stem cells for Leigh syndrome, Stem Cell Res. source
- cites [162] McKnight, C.L., Low, Y.C., Elliott, D.A., Thorburn, D.R., and Frazier, A.E. (2021). Modelling mitochondrial disease in human pluripotent stem cells: What have we learned?. Int. J. Mol. Sci., 22. source
- Premisecitation
Dunn and Pinkert generated two versions of the nuclear-recoded mouse ATP6 gene: a wildtype and mt8993T > G that causes Leigh's syndrome and NARP in humans.
“Dunn and Pinkert generated two versions for the nuclear-recoded mouse ATP6 gene: a wildtype and mt8993T > G that causes Leigh’s syndrome and NARP in humans [117,167].”
Quote in the paperNot a substantial claim1 of 2 sources checked- cites [117] Dunn, 2012, Nuclear expression of a mitochondrial DNA gene: Mitochondrial targeting of allotopically expressed mutant ATP6 in transgenic mice, J. Biomed. Biotechnol. source
- cites [167] Dunn, 2015, Allotopic expression of ATP6 in the mouse as a transgenic model of mitochondrial disease, Methods in Molecular Biology source
- Premisecitation
Compounds currently in clinical trials for mitochondrial disease are predominantly antioxidants (such as Idebenone, EPI-743 and RPI-103) and small molecules that stabilize organelle membrane architecture (Elampritide/SS31).
“Compounds currently in clinical trials are predominantly antioxidants (such as Idebenone, EPI-743 and RPI-103) and small molecules that have the capability of stabilizing the organelle membrane architecture (Elampritide/SS31) [178].”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [178] Birk, 2013, The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin, J. Am. Soc. Nephrol. source
The Discussion (page not provided) reports that SS-31 preserved mitochondrial cristae membranes and prevented swelling in rats with renal ischemia, supporting the membrane-stabilization part of the claim. Our copy does not support the broader assertion that clinical-trial compounds are predominantly antioxidants, identify Idebenone, EPI-743 or RPI-103 as trial compounds, or establish trials for mitochondrial disease. (LLM, conf=0.86)
Experimental — accuracy not yet measured
- Premisecitation
Individual PSCs display considerable heterogeneity in mutation loads that can impact their utilization in disease modeling and as drug screening platforms.
“Furthermore, individual PSCs display considerable heterogeneity in mutation loads that can impact their utilization in disease modeling and as drug screening platforms [163,164].”
Quote in the paperNot a substantial claim2 of 2 sources checked- cites [163] Wei, 2021, Cell reprogramming shapes the mitochondrial DNA landscape, Nat. Commun. source
- cites [164] Kosanke, 2021, iPSC culture expansion selects against putatively actionable mutations in the mitochondrial genome, Stem Cell Rep. source
The Introduction and Results report differing mitochondrial variants and heteroplasmy levels among iPSC clones, including potentially damaging variants. The Discussion says heteroplasmy levels can rise enough to affect cell functionality. Our copy does not establish an impact on using those cells for disease modeling or drug screening; “drug screening” appears only in a reference title. (LLM, conf=0.83)
Experimental — accuracy not yet measured
- Premisecitation
Some animal studies targeting the ATP6 and ND4 genes using AE have shown promising data.
“Despite these difficulties, some animal studies targeting the ATP6 and ND4 genes using AE have shown promising data [128,165,166,167].”
Quote in the paperSubstantial claim3 of 4 sources checked- cites [128] Augustin, 2015, Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss, Mol. Ther.-Methods Clin. Dev. source
- cites [165] Koilkonda, 2014, LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: Biodistribution and toxicology profile, Investig. Ophthalmol. Vis. Sci. source
- cites [166] Yu, 2012, Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber’s hereditary optic neuropathy in a mouse model, Proc. Natl. Acad. Sci. USA source
The Results and Discussion report promising ND4 outcomes in rodents, including reduced visual loss and optic atrophy. But this study delivered ND4 directly to mitochondria using targeted AAV, rather than using allotopic expression (AE), and it does not report an ATP6 animal study. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [167] Dunn, 2015, Allotopic expression of ATP6 in the mouse as a transgenic model of mitochondrial disease, Methods in Molecular Biology source
- Premisecitation
Mouse models have been used to study comparable phenotypes due to mutations in nuclear-encoded proteins involved in mitochondrial biogenesis, such as TFAM, PolG, Twinkle, and SURF-1.
“Mouse models have further been used to study comparable phenotypes due to mutations in nuclear-encoded proteins involved in mitochondrial biogenesis, such as TFAM [152], PolG [153], Twinkle [154,155,156], and SURF-1 [157].”
Quote in the paperNot a substantial claim4 of 5 sources checked- cites [152] Larsson, 1998, Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice, Nat. Genet. source
- cites [153] Williams, 2010, The mtDNA mutation spectrum of the progeroid polg mutator mouse includes abundant control region multimers, Cell Metab. source
- cites [154] Tyynismaa, 2005, Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions and a late-onset mitochondrial disease in mice, Proc. Natl. Acad. Sci. USA source
- cites [155] Song, 2012, Mutant twinkle increases dopaminergic neurodegeneration, mtDNA deletions and modulates Parkin expression, Hum. Mol. Genet. source
- cites [156] Milenkovic, 2013, Twinkle is an essential mitochondrial helicase required for synthesis of nascent D-loop strands and complete mtDNA replication, Hum. Mol. Genet. source
- Premisecitation
Mutant versions of the ND4 and ND6 genes have been expressed using mitochondria-targeted AAV to induce LHON phenotypes in mouse models.
“Similarly, mutant versions of the ND4 and ND6 genes have been expressed using mitochondria-targeted AAV, to induce LHON phenotypes in mouse models [151,165,166,168].”
Quote in the paperNot a substantial claim3 of 4 sources checked- cites [151] Yu, 2012, Mutant NADH dehydrogenase subunit 4 gene delivery to mitochondria by targeting sequence-modified adeno-associated virus induces visual loss and optic atrophy in mice, Mol. Vis.
- cites [165] Koilkonda, 2014, LHON gene therapy vector prevents visual loss and optic neuropathy induced by G11778A mutant mitochondrial DNA: Biodistribution and toxicology profile, Investig. Ophthalmol. Vis. Sci. source
The Construction of the Viral Vector section and the mouse rescue-experiment passage describe mitochondria-targeted AAV carrying mutant ND4 to induce LHON in mice. The Discussion reports resulting visual loss and optic atrophy. Our copy does not support the ND6 part of the claim (searched: ND6). (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [166] Yu, 2012, Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber’s hereditary optic neuropathy in a mouse model, Proc. Natl. Acad. Sci. USA source
The Results section reports that an AAV carrying mutant ND4 induced visual loss and optic atrophy in mice. But it describes that mutant ND4 vector as allotopic; the mitochondria-targeted AAV delivered wild-type ND4 to prevent those effects. The passages do not report a mutant ND6 experiment. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [168] Yu, 2020, Mitochondrial transfer of the Mutant human ND6T14484C gene causes visual loss and optic neuropathy, Transl. Vis. Sci. Technol. source
- Premisecitation
The AAV insert capacity limitation is more evident when the mutation affects mtDNA transcription or translation, such as mutations in the origin of replication for the light and heavy strands or in any of the tRNA genes that impact global protein translation in the mitochondrial matrix.
“This is more evident when the mutation affects mtDNA transcription or translation, such as mutations in the origin of replication for the light and heavy strands [174], or in any of the tRNA genes that impact global protein translation in the mitochondrial matrix [175].”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [174] Matkarimov, 2020, DNA Repair and Mutagenesis in Vertebrate Mitochondria: Evidence for Asymmetric DNA Strand Inheritance, Adv. Exp. Med. Biol. source
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured - cites [175] Zhao, 2019, Hypertension-associated mitochondrial DNA 4401A>G mutation caused the aberrant processing of tRNAMet, all 8 tRNAs and ND6 mRNA in the light-strand transcript, Nucleic Acids Res. source
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
- Interpretationreasoning
Genetic tools widely used to elucidate nuclear gene function, such as targeted knockouts, siRNA-mediated gene silencing, and site-directed mutagenesis, are non-viable options for mtDNA genes, which are sequestered within the organelle and therefore inaccessible.
“Genetic tools widely used to elucidate nuclear gene function, such as targeted knockouts, siRNA-mediated gene silencing, and site-directed mutagenesis, are non-viable options for mtDNA genes, which are sequestered within the organelle and therefore inaccessible.”
Quote in the paperSubstantial claim - Interpretationnone given
In the clinical trials, patients appear to have recovered vision in both eyes despite internal controls where one eye was treated and the other not.
“The studies aimed for internal controls where one eye was treated and the other not, but surprisingly patients appear to have recovered vision in both eyes.”
Quote in the paperNot a substantial claim - Interpretationreasoning
The study of mtDNA-mediated dysfunction is largely reliant on decades-old methods, mainly the use of patient-derived cybrid cell lines with specific mutations.
“Thus, the study of mtDNA-mediated dysfunction is largely reliant on decades-old methods, mainly the use of patient-derived cybrid cell lines with specific mutations.”
Quote in the paperSubstantial claim - Premisecitation
Researchers have employed co-expression of mutant allotopic genes over WT versions in ND4 and ATP6 transgenic mice to recapitulate specific disease states such as LHON and NARP.
“Researchers have also employed co-expression of mutant allotopic genes over WT versions, as in the case of ND4 [151] and ATP6 transgenic mice [117,151], in attempts to recapitulate specific disease states, such as LHON and NARP.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [151] Yu, 2012, Mutant NADH dehydrogenase subunit 4 gene delivery to mitochondria by targeting sequence-modified adeno-associated virus induces visual loss and optic atrophy in mice, Mol. Vis.
- cites [117] Dunn, 2012, Nuclear expression of a mitochondrial DNA gene: Mitochondrial targeting of allotopically expressed mutant ATP6 in transgenic mice, J. Biomed. Biotechnol. source
Checked before — its earlier verdict is held back until a new check runs.
- Interpretationnone given
As of now, only the ND4, ND6, and ATP6 genes have been demonstrated in animal models for allotopic expression.
“As of now, to our knowledge, only the ND4, ND6, and ATP6 genes have been demonstrated in animal models for allotopic expression.”
Quote in the paperNot a substantial claim - Interpretationreasoning
Numerous challenges have frustrated efforts to generate meaningful animal models of mitochondrial disease, especially for systems with loss-of-function mutations.
“Numerous challenges have also frustrated efforts to generate meaningful animal models of mitochondrial disease, especially for systems with loss-of-function mutations.”
Quote in the paperSubstantial claim - Interpretationreasoning
Achieving meaningful therapy for mutations affecting mtDNA transcription or translation may require transgene expression for more than one gene or, in certain instances, for all 13 mtDNA protein subunits.
“Under such circumstances, achieving meaningful therapy may therefore require transgene expression for more than one gene or, in certain instances, for those of all 13 mtDNA protein subunits.”
Quote in the paperSubstantial claim - Premisereasoning
Available systems for studying mitochondrial disease include naturally occurring mild mutations with less severe phenotypes, such as missense mutations in ATP8 and ND6.
“Available systems therefore include the study of naturally occurring mild mutations with less severe phenotypes, such as those observed due to missense mutations in the ATP8 [149] and ND6 genes [150].”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites [149] Weiss, 2012, The mitochondrial Atp8 mutation induces mitochondrial ROS generation, secretory dysfunction, and β-cell mass adaptation in conplastic B6-mt FVB mice, Endocrinology source
- cites [150] Lin, 2012, Mouse mtDNA mutant model of Leber hereditary optic neuropathy, Proc. Natl. Acad. Sci. USA source
- Premisecitation
Efforts using enucleated human cybrids and mouse pronuclear cells to generate mouse models for the 4.7 kb 'common deletion' failed to achieve progeny beyond F3.
“Efforts using enucleated human cybrids and mouse pronuclear cells to generate mouse models for the 4.7 kb “common deletion” that overtakes a rising number of postmitotic cells with age failed to achieve progeny beyond F3 [148].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [148] Inoue, 2000, Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes, Nat. Genet. source
- Interpretationreasoning
Studies probing the utility of AE for mitochondrial rescue are challenged by the lack of good animal models.
“Studies probing the utility of AE for mitochondrial rescue are challenged by the lack of good animal models.”
Quote in the paperSubstantial claim - Premisecitation
Transmitochondrial mice with the dual mutation T6589C (COX1) and 13885insC frameshift mutation (ND6) at equivalent levels lost the more severe ND6 13885insC frameshift mutation completely within four generations.
“for example, transmitochondrial mice with the dual mutation T6589C (COX1) and 13885insC frameshift mutation (ND6) genes, respectively, at equivalent levels lost the more severe ND6 13885insC frameshift mutation completely within four generations [147].”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [147] Fan, 2008, A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations, Science source
- Interpretationreasoning
If the more direct limitations to AE of individual subunits are overcome, gene replacement therapy could be a viable option to improve mitochondrial function.
“This suggests that if the more direct limitations to AE of individual subunits are overcome, gene replacement therapy could be a viable option to improve mitochondrial function.”
Quote in the paperSubstantial claim
- It may state two separate claims as one. 17
- Probably not a substantial claim. 9
It may state two separate claims as one.
PremisecitationTherapeutic use of AAV is limited by insert capacity (<5 kb), which prevents inclusion of more than one gene in these viral vehicles.
“However, therapeutic use of AAV is limited by insert capacity (<5 kb) [173], which prevents inclusion of more than one gene in these viral vehicles.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [173] Wu, 2010, Effect of Genome Size on AAV Vector Packaging, Mol. Ther. source
The Results section estimates an AAV packaging limit of about 5.2 kb, and the Discussion calls this limit a major hindrance to clinically relevant applications. The paper does not say that the limit prevents inclusion of more than one gene; that depends on the total size of the genes and other vector components. Its measured limit is also not strictly below 5 kb. (LLM, conf=0.88)
Experimental — accuracy not yet measured
It may state two separate claims as one.
PremisecitationCwerman-Thibault et al. modified the ND4 gene with elements of the human COX10 mRNA to improve delivery/import of the protein to mitochondria and showed that AAV2-mediated delivery of ND4 is expressed for up to 12 months in rats engineered to carry the G11778A LHON mutation.
“Cwerman-Thibault et al. [128] modified the ND4 gene with elements of the human COX10 mRNA to improve the delivery/import of the protein to mitochondria and showed that AAV2-mediated delivery of ND4 is expressed for up to 12 months in rats engineered to carry the G11778A LHON mutation.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [128] Augustin, 2015, Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss, Mol. Ther.-Methods Clin. Dev. source
It may state two separate claims as one.
PremisecitationGuy et al. showed that allotopic expression of the human ND4 gene in mice, administered via intravitreal injection, rescues visual dysfunction and prevents the LHON phenotype caused by the G11778A mutation.
“Guy et al. have shown that allotopic expression of the human ND4 gene in mice, administered via intravitreal injection, rescues visual dysfunction and prevents the LHON phenotype caused by the G11778A mutation [125,126].”
Quote in the paperSubstantial claim1 of 2 sources checked- cites [125] Qi, 2007, The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse, Investig. Ophthalmol. Vis. Sci. source
- cites [126] Koilkonda, 2010, Induction of rapid and highly efficient expression of the human ND4 complex I subunit in the mouse visual system by self-complementary adeno-associated virus, Arch. Ophthalmol. source
The Methods (Intraocular Injections) and Comment report intravitreal delivery and allotopic expression of normal human ND4 in mice. But the Results (Effects of Gene Expression on RGCs: Electrophysiology) found no significant change in visual-function measures, and the Comment says there was no measurable biological effect at one week. This paper does not show rescue of visual dysfunction or prevention of a G11778A-induced LHON phenotype. (LLM, conf=0.89)
Experimental — accuracy not yet measured
It may state two separate claims as one.
PremisecitationAdvances in identifying safe harbor loci in the human genome have facilitated in vitro transgene expression for large genes, such as human dystrophin and beta-hexosaminidases in Tay-Sachs and Sandhoff's syndromes, as well as expression of multiple glycosyl hydrolases in the CEP112 locus in animal models.
“advances in identifying safe harbor loci in the human genome have facilitated in vitro transgene expression for large genes, such as the human dystrophin [169] and beta-hexosaminidases in Tay-Sachs and Sandhoff’s syndromes [170], as well as the expression of multiple glycosyl hydrolases in the CEP112 locus in animal models [171].”
Quote in the paperNot a substantial claim3 of 3 sources checked- cites [169] Zhao, C., Farruggio, A.P., Bjornson, C.R.R., Chavez, C.L., Geisinger, J.M., Neal, T.L., Karow, M., and Calos, M.P. (2014). Recombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells. PLoS ONE, 9. source
The Results (Addition of dystrophin cDNA to mdx iPSC; page unavailable) report integration of a full-length dystrophin transgene at a selected safe site, and the Discussion reports dystrophin expression in the engineered cells. But the transgene was mouse dystrophin cDNA in mouse iPSC, not human dystrophin at a safe-harbor locus in the human genome. The other genes in the citing sentence have separate citations and are not attributed to this paper. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites [170] Ou, 2020, A novel gene editing system to treat both Tay–Sachs and Sandhoff diseases, Gene Ther. source
The Results (Construct design and verification; page unavailable) report β-hexosaminidase expression from a HEXB transgene using a safe-harbor editing strategy in Sandhoff mice. The cited paper also studies a HEXM construct with potential relevance to both Tay–Sachs and Sandhoff diseases. It does not establish in vitro transgene expression at a safe-harbor locus in the human genome: its in vitro mouse-cell assay tested DNA cleavage, while the reported transgene expression was in mice. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [171] Li, 2020, CRISPR/Cas9-mediated integration of large transgene into pig CEP112 locus, G3 Genes Genomes Genet. source
It may state two separate claims as one.
PremisecitationExperiments characterizing the phenotype of rescue mice gave mixed results and failed to definitively show an improvement in mice carrying the ATP6 mutation or to demonstrate robust expression of ATP6 in any of the tissues examined.
“However, the various experiments used to characterize the phenotype of the rescue mice gave mixed results and failed to definitively show an improvement in mice carrying the ATP6 mutation [117] or to demonstrate robust expression of ATP6 in any of the tissues examined.”
Quote in the paperNot a substantial claim1 of 1 sources checked- cites [117] Dunn, 2012, Nuclear expression of a mitochondrial DNA gene: Mitochondrial targeting of allotopically expressed mutant ATP6 in transgenic mice, J. Biomed. Biotechnol. source
The Results and Discussion report mixed motor-test outcomes and no detectable differences in several mitochondrial-function measures, supporting the characterization of inconclusive results. But this paper studies mice engineered to express mutant or wild-type ATP6, not rescue mice carrying an existing ATP6 mutation; it therefore does not test whether such mice improved. It shows mitochondrial localization of expressed ATP6 in striatum but does not establish robust expression across the tissues examined. The supplied passages have no page numbers. (LLM, conf=0.86)
Experimental — accuracy not yet measured
Probably not a substantial claim. The paper may give no reason why it holds.
Interpretationnone givenExisting gene therapies for mtDNA mutations are currently confined to just one organ (the eye).
“Existing gene therapies for mtDNA mutations are currently confined to just one organ (the eye).”
Quote in the paperNot a substantial claimProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
Interpretationnone givenStrategies such as mini-chromosomes or safe harbor integration directly into the nuclear genome have the potential capability of introducing >100 kb at a time, though there is not yet precedent for delivering such large cargos into clinically viable vectors.
“Beyond the current scope of prospective gene therapies, strategies such as mini-chromosomes or safe harbor integration directly into the nuclear genome have the potential capability of introducing >100 kb at a time, though there is not yet, to our knowledge, precedent for delivering such large cargos into clinically viable vectors.”
Quote in the paperNot a substantial claimProbably not a substantial claim. It may state two separate claims as one.
InterpretationreasoningValidating allotopic expression technology in vivo has challenges due to inadequate animal models for all protein coding genes, but the ease of generating precise human iPSCs may allow testing these gene therapy approaches on a case-by-case basis in vitro.
“While validating the technology in vivo has its challenges due to inadequate animal models for all the protein coding genes, the ease of generating precise human iPSCs, particularly from patients with specific mtDNA mutations, may allow us to test these gene therapy approaches on a case-by-case basis in vitro.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Interpretationnone givenTargeted restriction endonucleases and base-editing enzymes show promise but are limited by narrow specificity and may require patient-to-patient customization.
“Recent gene editing approaches, such as targeted restriction endonucleases and base-editing enzymes show promise, though they are limited by their narrow specificity and may require patient-to-patient customization.”
Quote in the paperSubstantial claimProbably not a substantial claim. The paper may give no reason why it holds.
Interpretationnone givenSynchronizing allotopic expression for the 13 mtDNA genes with the nuclear-mitochondrial transcription and translation machinery can overcome limitations in competing with pre-existing mutant proteins in the respiratory chain complexes due to heteroplasmy.
“Synchronizing allotopic expression for the 13 mtDNA genes with the nuclear-mitochondrial transcription and translation machinery can overcome limitations in competing with pre-existing mutant proteins in the respiratory chain complexes due to heteroplasmy, a condition commonly observed in known mtDNA pathologies.”
Quote in the paperNot a substantial claim- Rests on an assumption: Expression of mtDNA subunits is tightly coordinated with nuclear gene expression in a tissue- and condition-specific manner, with carefully regulated nuclear-to-mitochondrial subunit stoichiometry.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
Interpretationnone givenThere is reason to believe that the viral vector and/or the mitochondria migrated from one eye to the other to yield the benefit.
“There is reason to believe that the viral vector and/or the mitochondria migrated from one eye to the other to yield the benefit”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
InterpretationreasoningMitochondria with mutations that severely disrupt ETC function are often not viable, consistent with selection against such mutations in the maternal line preventing generation of true organismal research models of primary mitochondrial disease.
“Due to the critical function of OXPHOS subunits in respiration and metabolism, mitochondria with mutations that severely disrupt ETC function are often not viable, consistent with selection against such mutations in the maternal line preventing generation of true organismal research models of primary mitochondrial disease.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Interpretationnone givenMutator mice are attractive models of accelerated mutation load that may mimic the accumulation of mtDNA mutations with age but are poor systems for testing and optimizing single-gene therapies.
“Such “mutator” mice are attractive models of accelerated mutation load that may mimic the accumulation of mtDNA mutations with age but are poor systems for testing and optimizing single-gene therapies.”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
InterpretationreasoningThe therapy has been shown to be safe and improvements in symptoms were observed in many patients.
“The therapy has been shown to be safe and improvements in symptoms were observed in many patients.”
Quote in the paperNot a substantial claimProbably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.
Interpretationnone givenThe findings reviewed here suggest that innovative molecular and genetic therapies targeting mtDNA may soon become available.
“The findings reviewed here suggest that innovative molecular and genetic therapies targeting mtDNA may soon become available.”
Quote in the paperNot a substantial claimProbably not a substantial claim. The paper may give no reason why it holds.
Interpretationnone givenThe unique properties of the mitochondrial organelle predispose its genome to mutations and compromised functions leading to several diseases collectively called mitochondriopathies.
“The unique properties of the organelle predispose its genome to mutations and compromised functions leading to several diseases collectively called mitochondriopathies.”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
PremisecitationGenSight Biologics completed two phase 3 clinical trials to treat blindness caused by mtND4 mutations and recently reported sustained positive results from the RESTORE study, though at the time of writing neither study had reported results in any clinical trial registries.
“GenSight Biologics has also completed two phase 3 clinical trials to treat blindness caused by mtND4 mutations (ClinicalTrials.gov, Identifiers NCT03293524 and NCT02064569) and recently reported sustained positive results from the RESTORE study [177], though at the time of this writing neither study has reported results in any clinical trial registries.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [177] Biousse, 2021, Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study, J. Neuroophthalmol. source
Checked before — its earlier verdict is held back until a new check runs.
Probably not a substantial claim. The paper may give no reason why it holds.
Interpretationnone givenAdvances in technologies capable of inserting large DNA cargos into the nuclear genome, such as safe harbor expression or mini chromosomes, will allow for testing multiple allotopic genes simultaneously.
“Furthermore, advances in technologies capable of inserting large DNA cargos into the nuclear genome, such as safe harbor expression or mini chromosomes, will allow for testing multiple allotopic genes simultaneously.”
Quote in the paperNot a substantial claimProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
Interpretationnone givenAE might have an additional problem: in some cases, more than one gene needs to be transferred.
“AE might have an additional problem: in some cases, more than one gene needs to be transferred.”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
InterpretationcitationND4 has been exclusively studied in the context of LHON, and AE constructs have been examined for their ability to alleviate optic nerve damage and rescue visual acuity by restoring OXPHOS function and ATP levels.
“ND4 has been exclusively studied in the context of LHON, and AE constructs have been examined for their ability to alleviate optic nerve damage and rescue visual acuity by restoring OXPHOS function and ATP levels.”
Quote in the paperNot a substantial claimIt may state two separate claims as one.
Interpretationnone givenThe immune privilege of the eye allows for many gene therapy trials to be conducted in patients suffering from mitochondriopathies of the eye, establishing precedent for evaluating translational approaches.
“At the organ level, the immune privilege of the eye allows for many gene therapy trials to be conducted in patients suffering from mitochondriopathies of the eye, simultaneously establishing precedent for this model in evaluating translational approaches.”
Quote in the paperNot a substantial claim- Rests on an assumption: The immune privilege of the eye allows for many gene therapy trials to be conducted in patients suffering from mitochondriopathies of the eye.
It may state two separate claims as one.
Interpretationnone givenFew small-molecule leads have been identified that hold curative promise, and small-molecule modulation leaves the root cause of pathology unaddressed.
“While modulating organelle function using small molecules is attractive at the outset and benefits from ease of administration, few leads have been identified that hold curative promise, and this treatment modality leaves the root cause of pathology unaddressed.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Study design and conductreasoningThe clinical trials lack any meaningful placebo control, making it difficult to conclude efficacy with high confidence.
“but as the studies lack any meaningful placebo control, it is difficult to conclude efficacy with high confidence.”
Quote in the paperSubstantial claimIt may state two separate claims as one.
Study design and conductreasoningMost cybrid lines contain shifting ratios of wild-type and mutant mtDNA (heteroplasmy), which result in variable cellular and organismal phenotypes and weaken claims of rescue through AE.
“The use of patient-specific cybrid cell lines, however, carries its own disadvantages, as most cybrid lines contain shifting ratios of wild-type and mutant mtDNA, i.e., heteroplasmy, which result in variable cellular and organismal phenotypes and weaken claims of rescue through AE.”
Quote in the paperSubstantial claim- Rests on an assumption: Most cybrid lines contain shifting ratios of wild-type and mutant mtDNA (heteroplasmy).
The paper relies on this without support.
Expression of mtDNA subunits is tightly coordinated with nuclear gene expression in a tissue- and condition-specific manner, with carefully regulated nuclear-to-mitochondrial subunit stoichiometry.
“expression of mtDNA subunits is tightly coordinated with nuclear gene expression in a tissue- and condition-specific manner, with carefully regulated nuclear-to-mitochondrial subunit stoichiometry.”
The paper relies on this without support.
Mitochondrial content and mtDNA copy number vary amongst cells and tissue types.
“As mitochondrial content and mtDNA copy number vary amongst cells and tissue types”
The paper relies on this without support.
Nuclear expression of mtDNA genes must result in a transcriptional response appropriate for the mitochondrial load, which fluctuates depending on energy requirements, substrate availability, and cellular signaling.
“nuclear expression of mtDNA genes must result in a transcriptional response appropriate for the mitochondrial load, which also fluctuates depending on energy requirements, substrate availability, and cellular signaling.”
The paper relies on this without support.
Most cybrid lines contain shifting ratios of wild-type and mutant mtDNA (heteroplasmy).
“most cybrid lines contain shifting ratios of wild-type and mutant mtDNA, i.e., heteroplasmy”
The paper relies on this without support.
PSCs can exhibit altered mitochondrial and metabolic profiles because of the switch from glycolysis to oxidative phosphorylation upon differentiation.
“PSCs can exhibit altered mitochondrial and metabolic profiles because of the switch from glycolysis to oxidative phosphorylation upon differentiation.”
The paper relies on this without support.
mtDNA mutations are pleiotropic and can affect almost all tissues in the body.
“mtDNA mutations are pleiotropic and can affect almost all tissues in the body”
The paper relies on this without support.
The gene therapy field almost exclusively uses AAV vectors, serotypes 2 and 5.
“The gene therapy field almost exclusively uses AAV vectors, serotypes 2 and 5”
The paper relies on this without support.
The immune privilege of the eye allows for many gene therapy trials to be conducted in patients suffering from mitochondriopathies of the eye.
“the immune privilege of the eye allows for many gene therapy trials to be conducted in patients suffering from mitochondriopathies of the eye”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Challenges to successful allotopic expression include engineering and nuclear integration of an optimized construct, targeting an exogenous cytosolic protein to the mitochondria, and functional assembly and rescue of a mutant mitochondrial phenotype.
“Challenges to successful allotopic expression have been described previously, including (1) the engineering and nuclear integration of an optimized construct to express from the nucleus, (2) the targeting of an exogenous cytosolic protein to the mitochondria, and (3) the functional assembly and rescue of a mutant mitochondrial phenotype.32”
From Exogenous expression of ATP8, a mitochondrial encoded protein, from the nucleus in vivo (2024) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
The same trial identifier is assigned to a completed trial and a newly initiated trial
MinorNCT03293524 is listed as one of two completed phase 3 trials, then as the identifier of a newly initiated third phase 3 trial. The same identifier cannot distinguish those trials.
“GenSight Biologics has also completed two phase 3 clinical trials to treat blindness caused by mtND4 mutations (ClinicalTrials.gov, Identifiers NCT03293524 and NCT02064569)”
“GenSight Biologics has now initiated a third phase 3 trial in which one arm of the study will receive the same single eye treatment while the other arm receives only a mock treatment. The trial is expected to conclude in 2024 (ClinicalTrials.gov, Identifier NCT03293524).”
COX2 rescue claim conflicts with a cited reference title
MinorThe text says the modified yeast COX2 protein failed to restore complex function, but one of the references cited for that statement explicitly reports rescue of cytochrome oxidase by a modified Cox2 precursor.
“Studies of COX2 in yeast determined that this Complex IV subunit could be effectively expressed and imported upon replacement of hydrophobic residues in transmembrane segments of the protein [97,133,134]; however, despite achieving import, expression of the modified protein failed to restore function of the complex”
“134. Cruz-Torres V. Vázquez-Acevedo M. García-Villegas R. Pérez-Martínez X. Mendoza-Hernández G. González-Halphen D. The cytosol-synthesized subunit II (Cox2) precursor with the point mutation W56R is correctly processed in yeast mitochondria to rescue cytochrome oxidase”
Citations
Cites
Sequence and organization of the human mitochondrial genome
Anderson, S., Bankier, A. T., Barrell, B. G., de Bruijn, M. H. L., Coulson, A. R., Drouin, J., Eperon, I. C., Nierlich, D. P., Roe, B. A., Sanger, F., et al. (1981) · Nature · doi:10.1038/290457a0 · Cited by 9,740
Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy
Wallace, D. C., Singh, G., Lott, M. T., Hodge, J. A., Schurr, T. G., Lezza, A. M. S., Elsas, L. J., & Nikoskelainen, E. K. (1988) · Science · doi:10.1126/science.3201231 · Cited by 2,440
Goto, Y.-I., Nonaka, I., & Horai, S. (1990) · Nature · doi:10.1038/348651a0 · Cited by 2,070
Mitochondria: Dynamic Organelles in Disease, Aging, and Development
Chan, D. C. (2006) · Cell · doi:10.1016/j.cell.2006.06.010 · Cited by 1,987
Mitochondrial transcription factor A is necessary for mtDNA maintance and embryogenesis in mice
Larsson, N.-G., Wang, J., Wilhelmsson, H., Oldfors, A., Rustin, P., Lewandoski, M., Barsh, G. S., & Clayton, D. A. (1998) · Nature Genetics · doi:10.1038/ng0398-231 · Cited by 1,594
Shoffner, J. M., Lott, M. T., Lezza, A. M. S., Seibel, P., Ballinger, S. W., & Wallace, D. C. (1990) · Cell · doi:10.1016/0092-8674(90)90059-n · Cited by 1,476
Decline in skeletal muscle mitochondrial function with aging in humans
Short, K. R., Bigelow, M. L., Kahl, J., Singh, R., Coenen-Schimke, J., Raghavakaimal, S., & Nair, K. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501559102 · Cited by 1,333
Regulation of mitochondrial biogenesis
Jornayvaz, F. R., & Shulman, G. I. (2010) · Essays in Biochemistry · doi:10.1042/bse0470069 · Cited by 1,119
Mitochondria, oxygen free radicals, disease and ageing
Raha, S., & Robinson, B. H. (2000) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)01674-1 · Cited by 1,066
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
A new mitochondrial disease associated with mitochondrial DNA heteroplasmy.
Holt, I. J., Harding, A. E., Petty, R., & MORGAN-HUGHES, J. A. (1990) · PubMed · Cited by 996
Mitochondrial threshold effects
Rossignol, R., Faustin, B., Rocher, C., Malgat, M., Mazat, J., & Letellier, T. (2003) · Biochemical Journal · doi:10.1042/bj20021594 · Cited by 816
The Interplay Between Mitochondrial Dynamics and Mitophagy
Twig, G., & Shirihai, O. S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3779 · Cited by 778
Human mitochondrial DNA: roles of inherited and somatic mutations
Schon, E. A., DiMauro, S., & Hirano, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3275 · Cited by 757
A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing
Mok, B. Y., de Moraes, M. H., Zeng, J., Bosch, D. E., Kotrys, A. V., Raguram, A., Hsu, F., Radey, M. C., Peterson, S. B., Mootha, V. K., et al. (2020) · Nature · doi:10.1038/s41586-020-2477-4 · Cited by 746
Gureev, A. P., Shaforostova, E. A., & Popov, V. N. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00435 · Cited by 663
Oxidative capacity and ageing in human muscle
Conley, K. E., Jubrias, S. A., & Esselman, P. C. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.t01-1-00203.x · Cited by 651
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
Mitochondria: The Next (Neurode)Generation
Schon, E. A., & Przedborski, S. (2011) · Neuron · doi:10.1016/j.neuron.2011.06.003 · Cited by 568
Somatic mtDNA mutations cause aging phenotypes without affecting reactive oxygen species production
Trifunovic, A., Hansson, A., Wredenberg, A., Rovio, A. T., Dufour, E., Khvorostov, I., Spelbrink, J. N., Wibom, R., Jacobs, H. T., & Larsson, N.-G. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508886102 · Cited by 555
Mutations of SURF-1 in Leigh Disease Associated with Cytochrome c Oxidase Deficiency
Tiranti, V., Hoertnagel, K., Carrozzo, R., Galimberti, C., Munaro, M., Granatiero, M., Zelante, L., Gasparini, P., Marzella, R., Rocchi, M., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/302150 · Cited by 527
Birk, A. V., Liu, S., Soong, Y., Mills, W., Singh, P., Warren, J. D., Seshan, S. V., Pardee, J. D., & Szeto, H. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012121216 · Cited by 479
A mouse model of mitochondrial disease reveals germline selection against severe mtDNA mutations
Fan, W., Waymire, K. G., Narula, N., Li, P., Rocher, C., Coskun, P. E., Vannan, M. A., Narula, J., MacGregor, G. R., & Wallace, D. C. (2008) · Science · doi:10.1126/science.1147786 · Cited by 466
Bua, E., Johnson, J., Herbst, A., Delong, B., McKenzie, D., Salamat, S., & Aiken, J. M. (2006) · The American Journal of Human Genetics · doi:10.1086/507132 · Cited by 442
The low-spin heme of cytochrome c oxidase as the driving element of the proton-pumping process
Tomitake Tsukihara, A., Shimokata, K., Katayama, Y., Shimada, H., Muramoto, K., Aoyama, H., Mochizuki, M., Shinzawa‐Itoh, K., Yamashita, E., Yao, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635097100 · Cited by 417
Howell, N., Bindoff, L. A., McCullough, D. A., Kubacka, I., Poulton, J., Mackey, D. A., Taylor, L., & Turnbull, D. M. (1991) · PubMed · Cited by 400
Chinnery, P. F., & Hudson, G. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt017 · Cited by 395
A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy.
Huoponen, K., Vilkki, J., Aula, P., Nikoskelainen, E. K., & Savontaus, M. L. (1991) · Europe PMC (PubMed Central) · Cited by 391
An ND-6 mitochondrial DNA mutation associated with leber hereditary optic neuropathy
Johns, D. R., Neufeld, M. J., & Park, R. D. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)90479-5 · Cited by 349
A critical analysis of codon optimization in human therapeutics
Mauro, V. P., & Chappell, S. A. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.09.003 · Cited by 343
Tyynismaa, H., Mjosund, K. P., Wanrooij, S., Lappalainen, I., Ylikallio, E., Jalanko, A., Spelbrink, J. N., Paetau, A., & Suomalainen, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505551102 · Cited by 342
Inoue, K., Nakada, K., Ogura, A., Isobe, K., Goto, Y.-I., Nonaka, I., & Hayashi, J.-I. (2000) · Nature Genetics · doi:10.1038/82826 · Cited by 333
Extensive pathogenicity of mitochondrial heteroplasmy in healthy human individuals
Ye, K., Lü, J., Ma, F., Keinan, A., & Gu, Z. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403521111 · Cited by 303
Selective Elimination of Mitochondrial Mutations in the Germline by Genome Editing
Reddy, P., Ocampo, A., Suzuki, K., Luo, J., Bacman, S. R., Williams, S. L., Sugawara, A., Okamura, D., Tsunekawa, Y., Wu, J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.051 · Cited by 303
Mitochondrial DNA variation and cancer
Kopinski, P. K., Singh, L. N., Zhang, S., Lott, M. T., & Wallace, D. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00358-w · Cited by 301
Association of mitochondrial DNA copy number with cardiovascular disease
Ashar, F. N., Zhang, Y., Longchamps, R. J., Lane, J., Moes, A., Grove, M. L., Mychaleckyj, J. C., Taylor, K. D., Coresh, J., Rotter, J. I., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.3683 · Cited by 295
A proposed refinement of the mitochondrial free radical theory of aging
de Grey, A. D. N. J. (1997) · BioEssays · doi:10.1002/bies.950190211 · Cited by 286
Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis
Lü, J., Sharma, L. K., & Bai, Y. (2009) · Cell Research · doi:10.1038/cr.2009.69 · Cited by 282
Gopal, R. K., Kübler, K., Calvo, S. E., Polak, P. P., Livitz, D. G., Rosebrock, D., Sadow, P. M., Campbell, B., Donovan, S. E., Amin, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.013 · Cited by 271
High levels of Fis1, a pro-fission mitochondrial protein, trigger autophagy
Gomes, L. C., & Scorrano, L. (2008) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2008.05.442 · Cited by 242
Chinnery, P. F., Samuels, D. C., Elson, J. L., & Turnbull, D. M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11310-9 · Cited by 237
Manfredi, G., Fu, J., Ojaimi, J., Sadlock, J. E., Kwong, J. Q., Guy, J., & Schon, E. A. (2002) · Nature Genetics · doi:10.1038/ng851 · Cited by 235
Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements.
Nicolson, G. L. (2014) · PubMed Central · Cited by 235
Mouse mtDNA mutant model of Leber hereditary optic neuropathy
Lin, C. S., Sharpley, M. S., Fan, W., Waymire, K. G., Sadun, A. A., Carelli, V., Ross-Cisneros, F. N., Baciu, P., Sung, E., McManus, M. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217113109 · Cited by 228
Efficient Mitochondrial Genome Editing by CRISPR/Cas9
Jo, A., Ham, S., Lee, G. H., Lee, Y., Kim, S., Lee, Y.-S., Shin, J.-H., & Lee, Y. (2015) · BioMed Research International · doi:10.1155/2015/305716 · Cited by 225
Ellouze, S., Augustin, S., Bouaita, A., Bonnet, C., Simonutti, M., Forster, V., Picaud, S. A., Sahel, J., & Corral‐Debrinski, M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.08.013 · Cited by 224
Mitochondrial protein-import machinery: correlating structure with function
Baker, M. J., Frazier, A. E., Gulbis, J. M., & Ryan, M. T. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.07.010 · Cited by 221
Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy
Guy, J., Qi, X., Pallotti, F., Schon, E. A., Manfredi, G., Carelli, V., Martinuzzi, A., Hauswirth, W. W., & Lewin, A. S. (2002) · Annals of Neurology · doi:10.1002/ana.10354 · Cited by 215
How rapidly does the human mitochondrial genome evolve?
Howell, N., Kubacka, I., & Mackey, D. A. (1996) · PubMed Central · Cited by 213
Mutations of the mitochondrial ND1 gene as a cause of MELAS
Kirby, D. M., McFarland, R., Ohtake, A., Dunning, C. J. R., Ryan, M. T., Wilson, C. J., Ketteridge, D., Turnbull, D. M., Thorburn, D. R., & Taylor, R. W. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.020537 · Cited by 185
Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Wan, X., Pei, H., Zhao, M.-J., Yang, S., Hu, W.-K., He, H., Ma, S.-Q., Zhang, G., Dong, X.-Y., Chen, C., et al. (2016) · Scientific Reports · doi:10.1038/srep21587 · Cited by 182
OXPHOS gene expression and control in mitochondrial disorders
Reinecke, F., Smeitink, J. A. M., & van der Westhuizen, F. H. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.04.003 · Cited by 180
Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype
Kaufmann, P., Engelstad, K., Wei, Y., Kulikova, R., Oskoui, M., Sproule, D. M., Battista, V., Koenigsberger, D. Y., Pascual, J. M., Shanske, S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31823a0c7f · Cited by 179
Independent impacts of aging on mitochondrial DNA quantity and quality in humans
Zhang, R., Wang, Y., Ye, K., Picard, M. A., & Gu, Z. (2017) · BMC Genomics · doi:10.1186/s12864-017-4287-0 · Cited by 178
Bayona‐Bafaluy, M. P., Blits, B., Battersby, B. J., Shoubridge, E. A., & Moraes, C. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502896102 · Cited by 176
Milenkovic, D., Matic, S., Kuhl, I., Ruzzenente, B., Freyer, C., Jemt, E., Park, C. B., Falkenberg, M., & Larsson, N.-G. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt051 · Cited by 173
Scarpulla, R. C. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.10.011 · Cited by 173
Identification of a Novel Mutation in the mtDNA ND5 Gene Associated with MELAS
Santorelli, F. M., Tanji, K., Kulikova, R., Shanske, S., Vilarinho, L., Hays, A. P., & DiMauro, S. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7167 · Cited by 171
Limitations to in vivo Import of Hydrophobic Proteins into Yeast Mitochondria
Claros, M. G., Perea, J., Shu, Y., Samatey, F. A., Popot, J., & Jacq, C. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20321.x · Cited by 169
Perales‐Clemente, E., Fernández‐Silva, P., Acín‐Pérez, R., Martos, A. P., & Enrı́quez, J. A. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq769 · Cited by 154
Yu, H., Koilkonda, R. D., Chou, T.-H., Porciatti, V., Ozdemir, S. S., Chiodo, V., Boye, S. L., Boye, S. E., Hauswirth, W. W., Lewin, A. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119577109 · Cited by 154
Mitochondrial function as a determinant of life span
Lanza, I. R., & Nair, K. S. (2009) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-009-0724-5 · Cited by 152
Westermann, B. (2002) · EMBO Reports · doi:10.1093/embo-reports/kvf113 · Cited by 149
The mitochondrial respiratory chain is a modulator of apoptosis
Kwong, J. Q., Henning, M. S., Starkov, A. A., & Manfredi, G. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704059 · Cited by 148
Ganetzky, R. D., Stendel, C., McCormick, E. M., Zolkipli‐Cunningham, Z., Goldstein, A. C., Klopstock, T., & Falk, M. J. (2019) · Human Mutation · doi:10.1002/humu.23723 · Cited by 141
The proton pumping pathway of bovine heart cytochrome c oxidase
Shimokata, K., Katayama, Y., Murayama, H., Suematsu, M., Tomitake Tsukihara, A., Muramoto, K., Aoyama, H., Yoshikawa, S., & Shimada, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611627104 · Cited by 137
Localization of mRNAs coding for mitochondrial proteins in the yeast Saccharomyces cerevisiae
Gadir, N., Haim-Vilmovsky, L., Kraut-Cohen, J., & Gerst, J. E. (2011) · RNA · doi:10.1261/rna.2621111 · Cited by 137
Mitochondrial DNA heteroplasmy in disease and targeted nuclease‐based therapeutic approaches
Nissanka, N., & Moraes, C. T. (2020) · EMBO Reports · doi:10.15252/embr.201949612 · Cited by 134
Bonnet, C., Augustin, S., Ellouze, S., Bénit, P., Bouaita, A., Rustin, P., Sahel, J.-A., & Corral-Debrinski, M. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.04.018 · Cited by 130
Somatic mitochondrial DNA mutations in early parkinson and incidental lewy body disease
Lin, M. T. S., Cantuti‐Castelvetri, I., Zheng, K., Jackson, K. E., Tan, Y. B., Arzberger, T., Lees, A. J., Betensky, R. A., Beal, M. F., & Simon, D. K. (2012) · Annals of Neurology · doi:10.1002/ana.23568 · Cited by 129
Mauro, V. P. (2018) · BioDrugs · doi:10.1007/s40259-018-0261-x · Cited by 129
Pharmacological advances in mitochondrial therapy
Singh, A., Faccenda, D., & Campanella, M. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103244 · Cited by 128
Tissue specific differences in mitochondrial DNA maintenance and expression
Herbers, E., Kekäläinen, N. J., Hangas, A., Pohjoismäki, J. L., & Goffart, S. (2019) · Mitochondrion · doi:10.1016/j.mito.2018.01.004 · Cited by 121
Kunze, M., & Berger, J. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00259 · Cited by 119
Margeot, A., Blugeon, C., Sylvestre, J., Vialette, S., Jacq, C., & Corral‐Debrinski, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf690 · Cited by 119
Sgarbi, G., Baracca, A., Lenaz, G., Valentino, M. L., Carelli, V., & Solaini, G. (2006) · Biochemical Journal · doi:10.1042/bj20051748 · Cited by 118
Age-related accumulation of de novo mitochondrial mutations in mammalian oocytes and somatic tissues
Arbeithuber, B., Hester, J., Cremona, M. A., Stoler, N., Zaidi, A. A., Higgins, B., Anthony, K., Chiaromonte, F., Díaz, F. J., & Makova, K. D. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000745 · Cited by 115
Limitations of Allotopic Expression of Mitochondrial Genes in Mammalian Cells
Oca‐Cossio, J., Kenyon, L., Hao, H., & Moraes, C. T. (2003) · Genetics · doi:10.1093/genetics/165.2.707 · Cited by 112
Human artificial chromosomes for gene delivery and the development of animal models
Kazuki, Y., & Oshimura, M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.136 · Cited by 108
Hoekstra, J. G., Hipp, M. J., Montine, T. J., & Kennedy, S. R. (2016) · Annals of Neurology · doi:10.1002/ana.24709 · Cited by 108
Leber hereditary optic neuropathy: respiratory chain dysfunction and degeneration of the optic nerve
Howell, N. (1998) · Vision Research · doi:10.1016/s0042-6989(97)00444-6 · Cited by 107
Bacman, S. R., Williams, S. L., García, S., & Moraes, C. T. (2010) · Gene Therapy · doi:10.1038/gt.2010.25 · Cited by 107
Inhibition of mitochondrial fission favours mutant over wild-type mitochondrial DNA
Malena, A., Loro, E., Di Re, M., Holt, I. J., & Vergani, L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp281 · Cited by 107
Nagley, P., Farrell, L. B., Gearing, D. P., Nero, D., Meltzer, S., & Devenish, R. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.7.2091 · Cited by 106
Sarzi, E., Brown, M. D., Lebon, S., Chrétien, D., Münnich, A., Rötig, A., & Procaccio, V. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31565 · Cited by 105
Adapting CRISPR/Cas9 System for Targeting Mitochondrial Genome
Hussain, S.-R. A., YALVAÇ, M. E., Khoo, B. S., Eckardt, S., & McLaughlin, K. J. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.627050 · Cited by 105
Mitochondrial mutation rate revisited: hot spots and polymorphism
JAZIN, E. E., Soodyall, H., Jalonen, P., Lindholm, E., Stoneking, M., & Gyllensten, U. B. (1998) · Nature Genetics · doi:10.1038/ng0298-109 · Cited by 100
Bonnet, C., Kaltimbacher, V., Ellouze, S., Augustin, S., Bénit, P., Forster, V., Rustin, P., Sahel, J.-A., & Corral-Debrinski, M. (2007) · Rejuvenation Research · doi:10.1089/rej.2006.0526 · Cited by 98
Williams, S. L., Huang, J., Edwards, Y. J. K., Ulloa, R. H., Dillon, L. M., Prolla, T. A., Vance, J. M., Moraes, C. T., & Züchner, S. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.012 · Cited by 96
The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse
Qi, X., Sun, L., Lewin, A. S., Hauswirth, W. W., & Guy, J. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0789 · Cited by 96
Kaltimbacher, V., Bonnet, C., Lecoeuvre, G., Forster, V., Sahel, J., & Corral‐Debrinski, M. (2006) · RNA · doi:10.1261/rna.18206 · Cited by 95
Comparative Analysis of Mitochondrial N-Termini from Mouse, Human, and Yeast
Calvo, S. E., Julien, O., Clauser, K. R., Shen, H., Kamer, K. J., Wells, J. A., & Mootha, V. K. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.063818 · Cited by 95
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells
Calabrese, C., Iommarini, L., Kurelac, I., Calvaruso, M. A., Capristo, M., Lollini, P., Nanni, P., Bergamini, C., Nicoletti, G., Giovanni, C. D., et al. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-11 · Cited by 94
Hirano, M., Carelli, V., GIORGIO, R. D., Pironi, L., Accarino, A. M., Cenacchi, G., D’Alessandro, R., Filosto, M., Martí, R., Nonino, F., et al. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12300 · Cited by 94
Rapamycin drives selection against a pathogenic heteroplasmic mitochondrial DNA mutation
Dai, Y., Zheng, K., Clark, J., Swerdlow, R. H., Pulst, S. M., Sutton, J. P., Shinobu, L. A., & Simon, D. K. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt450 · Cited by 92
Mapping overlapping functional elements embedded within the protein-coding regions of RNA viruses
Firth, A. E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku981 · Cited by 91
Mitochondrial disorders: Challenges in diagnosis & treatment
Kumarasamy Thangaraj, K., Khan, N., Govindaraj, P., & Meena, A. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.154489 · Cited by 88
Cwerman-Thibault, H., Augustin, S., Lechauve, C., Ayache, J., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.3 · Cited by 86
Comte, C., Tonin, Y., Heckel, A., Boucheham, A., Smirnov, A., Auré, K., Lombès, A., Martin, R. P., Entelis, N., & Tarassov, I. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks965 · Cited by 83
Therapeutic Manipulation of mtDNA Heteroplasmy: A Shifting Perspective
Jackson, C. B., Turnbull, D. M., Minczuk, M. A., & Gammage, P. A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.02.006 · Cited by 81
SOD2 gene transfer protects against optic neuropathy induced by deficiency of complex I
Qi, X., Lewin, A. S., Sun, L., Hauswirth, W. W., & Guy, J. R. (2004) · Annals of Neurology · doi:10.1002/ana.20175 · Cited by 78
Knock-In Strategy for Editing Human and Zebrafish Mitochondrial DNA Using Mito-CRISPR/Cas9 System
Bian, W.-P., Chen, Y., Luo, J., Wang, C., Xie, S., & Pei, D. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00411 · Cited by 78
Biousse, V., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Vignal-Clermont, C., Klopstock, T., Sadun, A. A., Sergott, R. C., Hage, R., et al. (2021) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001367 · Cited by 78
Bietenhader, M., Martos, A. A. R., Tétaud, E., Aiyar, R. S., Sellem, C. H., Kucharczyk, R., Clauder‐Münster, S., Giraud, M., Godard, F., Salin, B., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002876 · Cited by 77
Functional Role of Mitochondrial DNA in Cancer Progression
Lin, Y.-H., Lim, S., Chen, C., Chi, H., Yeh, C., & Lin, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031659 · Cited by 75
Carelli, V., Maresca, A., Caporali, L., Trifunov, S., Zanna, C., & Rugolo, M. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.01.023 · Cited by 74
Resolving the Enigma of the Clonal Expansion of mtDNA Deletions
Kowald, A., & Kirkwood, T. B. L. (2018) · Genes · doi:10.3390/genes9030126 · Cited by 69
Two New Mutations in theMTATP6Gene Associated with Leigh Syndrome
Moslemi, A. ‐., Darín, N., Tulinius, M., Oldfors, A., & Holme, E. (2005) · Neuropediatrics · doi:10.1055/s-2005-872845 · Cited by 67
Ojaimi, J., Pan, J., Santra, S., Snell, W. J., & Schon, E. A. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-05-0306 · Cited by 65
Koilkonda, R., Yu, H., Talla, V., Porciatti, V., Feuer, W. J., Hauswirth, W. W., Chiodo, V., Erger, K. E., Boye, S. L., Lewin, A. S., et al. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15388 · Cited by 65
Mitochondrial DNA deletion mutations increase exponentially with age in human skeletal muscle
Herbst, A. J., Lee, C. C., Vandiver, A. R., Aiken, J. M., McKenzie, D. I., Hoang, A. N., Allison, D. B., Liu, N., & Wanagat, J. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01698-7 · Cited by 64
Is There Still Any Role for Oxidative Stress in Mitochondrial DNA-Dependent Aging?
Zsurka, G., Peeva, V., Kotlyar, A. B., & Kunz, W. S. (2018) · Genes · doi:10.3390/genes9040175 · Cited by 60
Transcription could be the key to the selection advantage of mitochondrial deletion mutants in aging
Kowald, A., & Kirkwood, T. B. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314970111 · Cited by 59
Sen, A., & Cox, R. T. (2016) · Biology Open · doi:10.1242/bio.015313 · Cited by 59
Cas9/gRNA-mediated genome editing of yeast mitochondria and Chlamydomonas chloroplasts
Yoo, B.-C., Yadav, N. S., Orozco, E. M., & Sakai, H. (2020) · PeerJ · doi:10.7717/peerj.8362 · Cited by 59
Qi, X. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.2.268 · Cited by 58
Gearing, D. P., & Nagley, P. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04695.x · Cited by 57
Iyer, S., Thomas, R. R., Portell, F. R., Dunham, L. D., Quigley, C. K., & Bennett, J. P. (2009) · Mitochondrion · doi:10.1016/j.mito.2009.01.012 · Cited by 56
Kytövuori, L., Lipponen, J., Rusanen, H., Komulainen, T., Martikainen, M. H., & Majamaa, K. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8249-2 · Cited by 56
Tonin, Y., Heckel, A., Vysokikh, M. Y., Dovydenko, I. S., Meschaninova, M. I., Rötig, A., Münnich, A., Venyaminova, A. G., Tarassov, I., & Entelis, N. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.528968 · Cited by 55
Galanis, M., Devenish, R. J., & Nagley, P. (1991) · FEBS Letters · doi:10.1016/0014-5793(91)80529-c · Cited by 54
Sánchez-Contreras, M., Sweetwyne, M. T., Kohrn, B. F., Tsantilas, K. A., Hipp, M. J., Schmidt, E. K., Fredrickson, J., Whitson, J. A., Campbell, M. D., Rabinovitch, P. S., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab901 · Cited by 54
Weiss, H., Wester-Rosenloef, L., Koch, C., Koch, F., Baltrusch, S., Tiedge, M., & Ibrahim, S. (2012) · Endocrinology · doi:10.1210/en.2012-1296 · Cited by 52
Rai, P. K., Craven, L., Hoogewijs, K., Russell, O. M., & Lightowlers, R. N. (2018) · Essays in Biochemistry · doi:10.1042/ebc20170113 · Cited by 52
A novel gene editing system to treat both Tay–Sachs and sandhoff diseases
Ou, L., Przybilla, M. J., Tăbăran, A.-F., Overn, P., O’Sullivan, M. G., Jiang, X., Sidhu, R., Kell, P. J., Ory, D. S., & Whitley, C. B. (2020) · Gene Therapy · doi:10.1038/s41434-019-0120-5 · Cited by 52
Bax, B. E., Levene, M., Bain, M. D., Fairbanks, L. D., Filosto, M., Uçar, S. K., Klopstock, T., Kornblum, C., Mandel, H., Rahman, S., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081096 · Cited by 51
Chin, R. M., Panavas, T., Brown, J. M., & Johnson, K. K. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.059 · Cited by 50
A single mutation in the first transmembrane domain of yeast COX2 enables its allotopic expression
Supeková, Ľ., Supek, F., Greer, J. E., & Schultz, P. G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000735107 · Cited by 49
Koilkonda, R. D. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.135 · Cited by 48
Mitochondrial DNA Mutations in Aging
Khrapko, K., & Turnbull, D. M. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-394625-6.00002-7 · Cited by 47
Cell reprogramming shapes the mitochondrial DNA landscape
Wei, W., Gaffney, D. J., & Chinnery, P. F. (2021) · Nature Communications · doi:10.1038/s41467-021-25482-x · Cited by 47
Figueroa‐Martinez, F., Vázquez‐Acevedo, M., Cortés-Hernández, P., García‐Trejo, J. J., Davidson, E., King, M. P., & González‐Halphen, D. (2010) · Mitochondrion · doi:10.1016/j.mito.2010.09.003 · Cited by 46
Resolving complexity in mitochondrial disease: Towards precision medicine
Boggan, R. M., Lim, A. Z., Taylor, R. W., McFarland, R., & Pickett, S. J. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.09.003 · Cited by 46
Strategies for mitochondrial gene editing
Yang, X., Jiang, J., Li, Z., Liang, J., & Xiang, Y. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.06.003 · Cited by 45
Silvestri, G., Mongini, T., Odoardi, F., Modoni, A., G., D., Doriguzzi, C., Palmucci, L., Tonali, P., & Servidei, S. (2000) · Neurology · doi:10.1212/wnl.54.8.1693 · Cited by 44
Sharma, L. K., Tiwari, M., Rai, N. K., & Bai, Y. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy354 · Cited by 44
Bokori‐Brown, M., & Holt, I. J. (2006) · Rejuvenation Research · doi:10.1089/rej.2006.9.455 · Cited by 41
Law, R. H. P., Farrell, L. B., Nero, D., Devenish, R. J., & Nagley, P. (1988) · FEBS Letters · doi:10.1016/0014-5793(88)80086-3 · Cited by 40
Song, L., Shan, Y., Lloyd, K. C. K., & Cortopassi, G. A. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds365 · Cited by 39
Mouse models for mitochondrial diseases
Ruzzenente, B., Rötig, A., & Metodiev, M. D. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw176 · Cited by 39
Assembly of imported subunit 8 into the ATP synthase complex of isolated yeast mitochondria
Law, R. H. P., Devenish, R. J., & Nagley, P. (1990) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1990.tb15419.x · Cited by 38
Antón, Z., Mullally, G., Ford, H. C., van der Kamp, M. W., Szczelkun, M. D., & Lane, J. D. (2020) · Journal of Cell Science · doi:10.1242/jcs.248468 · Cited by 38
Reprogrammed expression of subunit 9 of the mitochondrial ATPase complex of Saccharomyces cerevisiae
Farrell, L. B., Gearing, D. P., & Nagley, P. (1988) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1988.tb13976.x · Cited by 37
Role of ectopically expressed mtDNA encoded cytochrome c oxidase subunit I (MT-COI) in tumorigenesis
Singh, R. K., Saini, S. K., Prakasam, G., Kalairasan, P., & Bamezai, R. N. K. (2019) · Mitochondrion · doi:10.1016/j.mito.2019.07.002 · Cited by 34
Mouse models of oxidative phosphorylation dysfunction and disease
Vempati, U. D., Torraco, A., & Moraes, C. T. (2008) · Methods · doi:10.1016/j.ymeth.2008.09.008 · Cited by 33
Mitochondrial DNA Replacement Techniques to Prevent Human Mitochondrial Diseases
Sendra, L., García-Mares, A., Herrero, M. J., & Aliño, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020551 · Cited by 33
Multiple Symmetric Lipomatosis (Madelung's Disease) Caused by the MERRF (A8344G) Mutation
Siao, P., Vucic, S., Hedley‐Whyte, E. T., Dreyer, M., & Cros, D. (2003) · Journal of Clinical Neuromuscular Disease · doi:10.1097/00131402-200309000-00001 · Cited by 31
Current strategies towards therapeutic manipulation of mtDNA heteroplasmy
Moraes, C. T. (2016) · Frontiers in bioscience · doi:10.2741/4529 · Cited by 31
Zullo, S. J., Parks, W. T., Chloupkova, M., Wei, B., Weiner, H., Fenton, W. A., Eisenstadt, J. M., & Merril, C. R. (2005) · Rejuvenation Research · doi:10.1089/rej.2005.8.18 · Cited by 30
Zhao, X., Cui, L., Xiao, Y., Mao, Q., Aishanjiang, M., Kong, W., Liu, Y., Chen, H., Hong, F., Jia, Z., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz742 · Cited by 29
CRISPR/Cas9-Mediated Integration of Large Transgene into Pig CEP112 Locus
Li, G., Zhang, X., Wang, H., Mo, J., Zhong, C., Shi, J., Zhou, R., Li, Z., Yang, H., Wu, Z., et al. (2020) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.119.400810 · Cited by 29
Whisper mutations: cryptic messages within the genetic code
Fåhræus, R., Marı́n, M., & Olivares‐Illana, V. (2015) · Oncogene · doi:10.1038/onc.2015.454 · Cited by 28
Stable nuclear expression of ATP8 and ATP6 genes rescues a mtDNA Complex V null mutant
Boominathan, A., Vanhoozer, S., Basisty, N., Powers, K., Crampton, A. L., Wang, X., Friedricks, N., Schilling, B., Brand, M. D., & O'Connor, M. S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw756 · Cited by 27
Self-citationTherapeutic Effects of Idebenone on Leber Hereditary Optic Neuropathy
Zhao, X., Zhang, Y., Lü, L., & Yang, H. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1736307 · Cited by 27
Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned?
McKnight, C. L., Low, Y. C., Elliott, D. A., Thorburn, D. R., & Frazier, A. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147730 · Cited by 27
Clinical Trials in Mitochondrial Disease
Enns, G. M., & Cohen, B. H. (2017) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1177/2326409817733013 · Cited by 26
Zhao, C., Farruggio, A. P., Bjornson, C. R. R., Chavez, C. L., Geisinger, J. M., Neal, T. L., Karow, M., & Calos, M. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096279 · Cited by 25
Dunn, D. A., & Pinkert, C. A. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/541245 · Cited by 25
Meshrkey, F., Cabrera Ayuso, A., Rao, R. R., & Iyer, S. (2021) · Stem Cell Research · doi:10.1016/j.scr.2021.102572 · Cited by 24
Mitochondrial DNA Haplotypes as Genetic Modifiers of Cancer
Tasdogan, A., McFadden, D. G., & Mishra, P. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.004 · Cited by 23
Interrogating Mitochondrial Biology and Disease Using CRISPR/Cas9 Gene Editing
Tang, J., Pyle, A., Taylor, R. W., & Oláhová, M. (2021) · Genes · doi:10.3390/genes12101604 · Cited by 21
Codon optimization is an essential parameter for the efficient allotopic expression of mtDNA genes
Lewis, C. J., Dixit, B., Batiuk, E., Hall, C. J., O'Connor, M. S., & Boominathan, A. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101429 · Cited by 20
Self-citationWang, Z., Sun, X., Wee, J., Guo, X., & Gu, Z. (2018) · Current Genetics · doi:10.1007/s00294-018-0862-4 · Cited by 18
Matkarimov, B. T., & Saparbaev, M. K. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-41283-8_6 · Cited by 18
Liu, J. M., & Liu, D. R. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm777 · Cited by 17
Chemical synthesis of a mitochondrial gene designed for expression in the yeast nucleus.
Gearing, D. P., McMullen, G. L., & NAGLEY, P. (1985) · PubMed · Cited by 17
iPSC culture expansion selects against putatively actionable mutations in the mitochondrial genome
Kosanke, M., Davenport, C., Szepes, M., Wiehlmann, L., Kohrn, T., Dorda, M., Gruber, J., Menge, K., Sievert, M., Melchert, A., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.08.016 · Cited by 17
Iommarini, L., Ghelli, A., Tropeano, C., Kurelac, I., Leone, G., Vidoni, S., Lombes, A., Zeviani, M., Gasparre, G., & Porcelli, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030764 · Cited by 16
Rubalcava-Gracia, D., Vázquez‐Acevedo, M., Funes, S., Pérez-Martı́nez, X., & González‐Halphen, D. (2018) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-09-0560 · Cited by 13
Mitochondrial Transfer of the Mutant Human ND6T14484C Gene Causes Visual Loss and Optic Neuropathy
Yu, H., Sant, D. W., Wang, G., & Guy, J. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.11.1 · Cited by 13
Cruz-Torres, V., Vázquez‐Acevedo, M., García-Villegas, R., Pérez-Martı́nez, X., Mendoza‐Hernández, G., & González‐Halphen, D. (2012) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2012.09.006 · Cited by 11
Rubalcava-Gracia, D., García-Rincón, J., Pérez‐Montfort, R., Hamel, P. P., & González‐Halphen, D. (2019) · Molecular Biology of the Cell · doi:10.1091/mbc.e18-12-0788 · Cited by 10
A novel m.11406 T > A mutation in mitochondrial ND4 gene causes MELAS syndrome
Lin, Y., Xu, X., Zhao, D., Liu, F., Luo, Y., Du, J., Wang, D., Ji, K., Zhao, Y., & Yan, C. (2020) · Mitochondrion · doi:10.1016/j.mito.2020.06.011 · Cited by 6
Protein coding mitochondrial-targeted RNAs rescue mitochondrial disease in vivo
Markantone, D. M., Towheed, A., Crain, A. T., Collins, J. M., Celotto, A. M., & Palladino, M. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.06.009 · Cited by 5
Allotopic expression of ATP6 in the mouse as a transgenic model of mitochondrial disease
Dunn, D. A., & Pinkert, C. A. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2288-8_18 · Cited by 3
Singh, P., Bahr, T., Zhao, X., Hu, P., Daadi, M., Huang, T., & Bai, Y. (2021) · Methods in Molecular Biology · doi:10.1007/7651_2021_384 · Cited by 3
Increased activity of surviving locus ceruleus neurons in Alzheimer's disease
Moser (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199901)45:1
(2012) · Europe PMC (PubMed Central)
Flagged first, then by citations
2 of the 180 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Vadakedath, S., Kandi, V., Jayashankar, C. A., Vijayan, S., Achyut, K. C., Uppuluri, S., Reddy, P. K. K., Ramesh, M., & Kumar, P. (2023) · Cureus · doi:10.7759/cureus.39812 · Cited by 15
Zhang, Z., Wang, X., Fan, P., Cheng, D., Dang, J., Dan, X., Xia, Y., & Fan, H. (2025) · Advanced Materials · doi:10.1002/adma.202511804 · Cited by 11
The constraints of allotopic expression
Nieto-Panqueva, F., Rubalcava-Gracia, D., Hamel, P. P., & González‐Halphen, D. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.09.004 · Cited by 9
Xia, H., Wang, Z., Wang, X., Gao, M., Jiang, S., Du, X., & Yang, X. (2025) · BMC Neurology · doi:10.1186/s12883-025-04176-7 · Cited by 9
Selheim, F., Aasebø, E., Bruserud, Ø., & Hernandez-Valladares, M. (2023) · Cancers · doi:10.3390/cancers16010008 · Cited by 9
Motta, G., Thangaraj, S. V., & Padmanabhan, V. (2023) · Toxics · doi:10.3390/toxics12010015 · Cited by 8
Exogenous expression of ATP8, a mitochondrial encoded protein, from the nucleus in vivo
Begelman, D. V., Dixit, B., Truong, C., King, C. D., Watson, M. A., Schilling, B., Brand, M. D., & Boominathan, A. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101372 · Cited by 5
Self-citationБудаква, Є. О. (2022) · Bulletin of Sumy National Agrarian University The series Livestock · doi:10.32845/bsnau.lvst.2022.2.2 · Cited by 2
Perri, M. R., Cerantonio, A., Cipriani, M. G., Manna, I., Aureli, A., Marziani, B., Andreozzi, F., Mannino, G. C., Mancuso, E., Averta, C., et al. (2026) · Archives of Pharmacal Research · doi:10.1007/s12272-026-01620-1 · Cited by 1
Huang, F., Sun, K., Diao, L., Lu, K., Fan, Y., & Xie, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1928003 · Cited by 1
Genetic influences on aging and neurodegenerative diseases
Rajalakshmi, D., Nisha, K., Hassan, S., Kumar, V. R., Faya, M., Mehdi, M. M., & Singh, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-36295-8.00002-x
From endosymbiont to signalling hub: evolution and functional integration of mitochondria
Hazır, Z. D., Türkel, İ., & Kubat, G. B. (2026) · Journal of Mitochondria Plastids and Endosymbiosis · doi:10.1080/28347056.2026.2737069
Pranandi, I., Tjhay, F., & Sendjaja, C. N. E. (2026) · Jurnal Locus Penelitian dan Pengabdian · doi:10.58344/locus.v5i10.6447
Metadata
- Authors
- Saravanan, S., Lewis, C. J., Dixit, B., O’Connor, M. S., Stolzing, A., & Boominathan, A.
- Affiliations
- SENS Research Foundation (US)
- Underdog Pharmaceuticals Inc., 110 Pioneer Way, Suite J, Mountain View, CA 94041, USA
- Loughborough University (GB)
- Corresponding author
- Boominathan, Amutha
- ORCID
- Venue
- Biomedicines
- Publisher
- MDPI AG
- Published
- 2022-02-18
- Volume
- 10
- Issue
- 2
- Pages
- 490
- ISSN
- 2227-9059 (ISSN-L)
- PMC
- PMC8962324
- OpenAlex
- W4213016410
- Cited by
- 13
- References
- 180
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 1
- FWCI
- 0.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicines (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- SENS Research Foundation (n/a)
- Foster Foundation (n/a)
- Forever Healthy Foundation (n/a)
- LifeSpan.io (n/a)
- Longecity Foundation (n/a)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- mitochondrial DNA, mitochondrial genome, aging, mitochondrial disease, mitochondrial DNA mutations, allotopic expression, mitochondrial gene therapy, mitochondrial DNA copy number, oxidative phosphorylation, electron transport chain, mitochondrial DNA editing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
